Form 4: Sutro Biopharma COO Jane Chung Reports Stock Transactions

Jane Chung, COO of Sutro Biopharma, reports the vesting and withholding of shares to cover tax obligations related to restricted stock units.

Summary

• Jane Chung, the President and COO of Sutro Biopharma, filed a Form 4 detailing changes in her beneficial ownership of the company's stock on March 1, 2025.
• The transactions involved the vesting of 6,875 and 25,000 restricted stock units (RSUs), which convert into common stock.
• A total of 9,450 shares were withheld by the issuer to cover income tax obligations related to the RSU settlement at a price of $1.59 per share.
• Following these transactions, Chung directly owns 92,767 shares of common stock and holds 13,750 RSUs vesting annually from March 1, 2024, and 75,000 RSUs vesting annually from March 1, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not convey any particularly positive or negative sentiment. It simply reports transactions.

Positives

• The vesting of RSUs indicates that Chung is meeting the service requirements of her employment agreement.

Future Outlook

The document does not contain any specific forward-looking statements regarding Sutro Biopharma's future performance.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. They are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry to attract and retain talent.
• The vesting schedules and terms of the RSUs are likely comparable to those offered by peer companies to executives in similar roles.

Stakeholder Impact

• The transactions reported in the Form 4 have a minimal direct impact on stakeholders.
• The tax withholding may slightly reduce the number of shares outstanding.

Key Dates